AbbVie Advances Upadacitinib (RINVOQ®) to Phase 3 Clinical Trials in Systemic Lupus ErythematosusPRNewsWire • 03/23/23
Risankizumab (SKYRIZI®) Achieves Primary and All Secondary Endpoints in Phase 3 Induction Study in Patients With Ulcerative ColitisPRNewsWire • 03/23/23
AbbVie Provides Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa) New Drug ApplicationPRNewsWire • 03/22/23
Alzamend Neuro Reports Third Fiscal Quarter Financial Results and Provides a Business UpdateBusiness Wire • 03/16/23
AbbVie Partners with Award-Winning Redglass Pictures on New Film Shedding Light on the Hidden Struggles of Those Living with EczemaPRNewsWire • 03/15/23